foxo4-dri peptide senolytic human trial UK | Research The disordered p53 transactivation domain
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect foxo4 dri senolytic peptide human trials Buy FOXO4 DRI Peptide (Proxofim) 10mg Senolytic Peptide FOXO4 DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes PMC
Pay in 4 interest-free payments of $5.55 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13



